Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). (Q46572104)
scientific article published on 13 August 2013
Language:
Current Data About Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20).
(P31) (Q13442814)
(P248)
(P698) 23942774
(P813) Saturday, December 23, 2017
(P854) http://europepmc.org/abstract/MED/23942774

(P50) (Q32649737)
(P1545) 4
(P248)
(P698) 23942774
(P813) Saturday, December 23, 2017
(P854) http://europepmc.org/abstract/MED/23942774

(P304) 2694-2698
(P248)
(P698) 23942774
(P813) Saturday, December 23, 2017
(P854) http://europepmc.org/abstract/MED/23942774

(P407) (Q1860)

(P433) 10
(P248)
(P698) 23942774
(P813) Saturday, December 23, 2017
(P854) http://europepmc.org/abstract/MED/23942774

(P478) 24
(P248)
(P698) 23942774
(P813) Saturday, December 23, 2017
(P854) http://europepmc.org/abstract/MED/23942774

(P577) Tuesday, August 13, 2013
(P248)
(P698) 23942774
(P813) Saturday, December 23, 2017
(P854) http://europepmc.org/abstract/MED/23942774

(P921) (Q42824827)

(Q181600)

(Q2459042)

(Q18975855)
(P887)

(P1433) (Q326122)
(P248)
(P698) 23942774
(P813) Saturday, December 23, 2017
(P854) http://europepmc.org/abstract/MED/23942774

(P1476) "Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)." (language: en)
(P248)
(P698) 23942774
(P813) Saturday, December 23, 2017
(P854) http://europepmc.org/abstract/MED/23942774

(P2093) D McDermott
(P1545) 1
(P248)
(P698) 23942774
(P813) Saturday, December 23, 2017
(P854) http://europepmc.org/abstract/MED/23942774

J Haanen
(P1545) 2
(P248)
(P698) 23942774
(P813) Saturday, December 23, 2017
(P854) http://europepmc.org/abstract/MED/23942774

T-T Chen
(P1545) 3
(P248)
(P698) 23942774
(P813) Saturday, December 23, 2017
(P854) http://europepmc.org/abstract/MED/23942774

S O'Day
(P1545) 5
(P248)
(P698) 23942774
(P813) Saturday, December 23, 2017
(P854) http://europepmc.org/abstract/MED/23942774

MDX010-20 Investigators
(P1545) 6
(P248)
(P698) 23942774
(P813) Saturday, December 23, 2017
(P854) http://europepmc.org/abstract/MED/23942774

(P2860) (Q35584299)
(P248)
(P854) https://api.crossref.org/works/10.1093%2FANNONC%2FMDT291
(P813) Sunday, January 21, 2018

(Q27861062)
(P248)
(P854) https://api.crossref.org/works/10.1093%2FANNONC%2FMDT291
(P813) Sunday, January 21, 2018

(Q35871798)
(P248)
(P854) https://api.crossref.org/works/10.1093%2FANNONC%2FMDT291
(P813) Sunday, January 21, 2018

(Q36286133)
(P248)
(P854) https://api.crossref.org/works/10.1093%2FANNONC%2FMDT291
(P813) Sunday, January 21, 2018

(Q24618690)
(P248)
(P854) https://api.crossref.org/works/10.1093%2FANNONC%2FMDT291
(P813) Sunday, January 21, 2018

(Q34188859)
(P248)
(P854) https://api.crossref.org/works/10.1093%2FANNONC%2FMDT291
(P813) Sunday, January 21, 2018

(Q35584186)
(P248)
(P854) https://api.crossref.org/works/10.1093%2FANNONC%2FMDT291
(P813) Sunday, January 21, 2018

(Q34472025)
(P248)
(P854) https://api.crossref.org/works/10.1093%2FANNONC%2FMDT291
(P813) Sunday, January 21, 2018

(Q28131634)
(P248)
(P854) https://api.crossref.org/works/10.1093%2FANNONC%2FMDT291
(P813) Sunday, January 21, 2018

(Q28265610)
(P248)
(P854) https://api.crossref.org/works/10.1093%2FANNONC%2FMDT291
(P813) Sunday, January 21, 2018

(Q38012057)
(P248)
(P854) https://api.crossref.org/works/10.1093%2FANNONC%2FMDT291
(P813) Sunday, January 21, 2018

(Q34567635)
(P248)
(P854) https://api.crossref.org/works/10.1093%2FANNONC%2FMDT291
(P813) Sunday, January 21, 2018

(Q51555848)
(P248)
(P854) https://api.crossref.org/works/10.1093%2FANNONC%2FMDT291
(P813) Sunday, January 21, 2018

(Q56897513)
(P248)
(P854) https://api.crossref.org/works/10.1093%2FANNONC%2FMDT291
(P813) Sunday, January 21, 2018

other details
description scientific article published on 13 August 2013

External Links
(P356) 10.1093/ANNONC/MDT291
(P698) 23942774